February 25, 2020
1 min watch
Save

VIDEO: Treat new onset IBD smarter, earlier, deeper

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video from the GUILD Conference 2020, Adam Cheifetz, MD, from Beth Israel Deaconess Medical Center discusses his presentation on change treatment paradigms in new onset inflammatory bowel disease.

Cheifetz told Healio Gastroenterology and Liver Disease that patients with new onset IBD need to be treated smarter, earlier and to deeper targets, like mucosal healing.

Treating early means getting to the disease before the patient develops complications and moves on to surgery. Regarding treating deeper, Cheifetz said he always has a conversation with patients about mucosal healing, but at the very least wants to achieve steroid-free clinical remission.

To treat smarter, Cheifetz uses proactive therapeutic drug monitoring to maintain adequate drug concentrations.

“There are plenty of data, particularly with the anti-TNF therapies, that low drug concentrations are associated with ... loss of response, development of antibodies and poor both short- and long-term outcomes,” he said. “The most important thing, regardless of which agent you choose, is to use it early and optimize it before giving up.”

Reference:
Cheifetz A. New onset IBD — Diagnosis, Prognosis and Therapy. Presented at: GUILD Conference 2020; February 16-19, 2020; Maui, Hawaii.

Disclosure: Cheifetz reports consulting for AbbVie, Arena, Arsanis, Bacainn, EMD Serono, Grifols, Janssen, Pfizer, Prometheus, Samsung and Takeda. He also reports receiving research support from Inform Diagnostics.